Jagsonpal Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: JAGSNPHARM BSE: 507789

₹237.74

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #84 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Jagsonpal Pharmaceuticals Limited (this stock)	1,565	35.0	15.6%	6.9%	—	66	3	85

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹1,555 Cr

EV / EBITDA

21.9x

EV / Sales

5.29x

Market cap / Sales

5.33x

Earnings yield

2.86%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 85 Cr, up 8.5% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 13 Cr, up 22.2% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	82	18	13	₹2.0000
March 31, 2026	64	12	9	₹1.2500
Dec. 31, 2025	73	15	11	₹1.6700
Sept. 30, 2025	74	17	13	₹1.8800
June 30, 2025	76	14	11	₹1.6000
March 31, 2025	59	9	7	₹0.9800
Dec. 31, 2024	74	39	32	₹4.7400
Sept. 30, 2024	75	15	11	₹4.2900
June 30, 2024	61	7	5	₹1.9400
March 31, 2024	43	5	4	₹1.3100
Dec. 31, 2023	47	5	4	₹1.4800
Sept. 30, 2023	58	10	7	₹2.8400
June 30, 2023	60	10	7	₹2.8500

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	85	67	76	77	78	61	76	76	63	46	50	60	62
Operating revenue	82	64	73	74	76	59	74	75	61	43	47	58	60
Other income	3	3	3	3	3	3	2	2	1	2	3	2	2
Operating expenses	65	53	57	58	61	50	58	58	51	41	44	49	52
Operating profit	17	11	16	16	14	9	16	16	10	3	3	8	9
Operating profit margin	21.0%	17.4%	22.3%	22.1%	18.8%	14.9%	21.4%	21.8%	16.7%	6.1%	7.2%	14.5%	14.4%
Depreciation	2	2	2	2	2	2	2	2	1	0	0	0	0
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Exceptional items, gain / (loss)	—	—	-2	—	—	-0	23	—	-3	—	—	—	—
Profit before tax	18	12	15	17	14	9	39	15	7	5	5	10	10
Tax	4	3	4	4	4	2	7	4	2	1	1	2	3
Net profit	13	9	11	13	11	7	32	11	5	4	4	7	7
EPS	2.00	1.25	1.67	1.88	1.60	0.98	4.74	4.29	1.94	1.31	1.48	2.84	2.85
Net profit (TTM)	45	43	41	62	61	55	52	24	20	22	—	—	—
EPS (TTM)	6.80	6.40	6.13	9.20	11.61	11.95	12.28	9.02	7.57	8.48	9.31	10.80	11.93

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	287	58	43
March 31, 2025	269	70	55
March 31, 2024	209	30	22
March 31, 2023	237	35	27

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	7.3%	9.2%	299^†	277^†	218^†	242^†	229^†	192^†	161^†	168^†	127^†	—
Operating revenue	6.7%	8.9%	287	269	209	237	226^†	188^†	159^†	167^†	127^†	144^†
Other income	—	—	12^†	8^†	9^†	6^†	3^†	4^†	3^†	1^†	0^†	—
Operating expenses	—	—	229^†	218^†	186^†	203^†	200^†	169^†	150^†	157^†	138^†	136^†
Operating profit	20.3%	24.9%	58^†	51^†	23^†	33^†	26^†	19^†	9^†	9^†	-11^†	9^†
Operating profit margin	—	—	20.2%^†	19.0%^†	11.1%^†	14.1%^†	11.4%^†	10.2%^†	5.4%^†	5.6%^†	-8.8%^†	5.9%^†
Depreciation	—	—	9^†	8^†	2^†	1^†	2^†	1^†	1^†	1^†	0^†	2^†
Interest	—	—	1^†	1^†	1^†	0^†	0^†	1^†	1^†	1^†	1^†	3^†
Exceptional items, gain / (loss)	—	—	-2^†	20^†	0^†	-6^†	0^†	0^†	0^†	0^†	0^†	13^†
Profit before tax	18.2%	21.3%	58	70	30	35	27^†	22^†	9^†	9^†	-12^†	14^†
Tax	—	—	14^†	14^†	7^†	8^†	8^†	5^†	2^†	2^†	—	3^†
Net profit	17.3%	20.4%	43	55	22	27	20^†	17^†	8^†	7^†	-12^†	12^†
EPS	-11.5%	-0.3%	6.40^†	11.95^†	8.48^†	9.22^†	7.47^†	6.51^†	2.99^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	20.2%^†	19.0%^†	11.1%^†	14.1%^†	11.4%^†	10.2%^†	5.4%^†	5.6%^†	-8.8%^†	5.9%^†
EBIT margin	20.4%^†	26.4%^†	14.7%^†	14.9%^†	12.2%^†	11.9%^†	6.3%^†	5.8%^†	-8.7%^†	11.8%^†
PBT margin	20.0%	26.0%	14.3%	14.7%	12.1%^†	11.6%^†	5.9%^†	5.4%^†	-9.2%^†	10.0%^†
Net margin	15.0%	20.6%	10.8%	11.3%	8.7%^†	9.1%^†	5.0%^†	4.3%^†	-9.1%^†	8.2%^†
Interest coverage	56.95x^†	73.92x^†	37.69x^†	85.34x^†	96.83x^†	43.59x^†	19.31x^†	13.08x^†	-16.69x^†	6.44x^†
Dividend payout	—	—	—	—	—	—	—	—	—	—
Earnings retention	—	—	—	—	—	—	—	—	—	—
Current ratio	5.06x	6.22x	—	—	—	—	—	—	—	—
Quick ratio	4.54x	5.64x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.00x	—	—	—	—	—	—	—	—
Return on equity	15.6%	23.1%	—	—	—	—	—	—	—	—
Return on assets	13.6%	19.9%	—	—	—	—	—	—	—	—
Return on capital employed	20.3%^†	28.1%^†	—	—	—	—	—	—	—	—
Asset turnover	0.91x	0.97x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	47	-36	-12	47
March 31, 2025	55	-45	-12	55
March 31, 2024	35	-25	-9	35
March 31, 2023	40	-52	0	40

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	317	276	263	0	0	143	28	10	1	15
March 31, 2025	278	240	227	0	0	161	26	11	1	15
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.